Inovio’ H1N1 Vaccine Shows Optimum Response Against Swine Flu

Inovio’ SynCon H1N1 influenza DNA vaccines has achieved protective antibody responses against H1N1 swine influenza virus, in 100% of pigs immunized with a two-dose vaccine regimen.

In the study, scientists immunized pigs with consensus H1N1 influenza DNA vaccine. It showed hemagglutination inhibition titers above the protection threshold in 100% of the vaccinated animals, against a swine H1N1 virus previously isolated from pigs.

On-going additional animal studies are testing the ability of Inovio’ vaccines to cross-protect from currently circulating human and swine H1N1 viruses, as well as the new influenza A/H1N1 of swine origin.

Joseph Kim, CEO of Inovio, said: “Our innovative SynCon technology has the potential to protect people from influenza strains not exactly like the ones that make up the existing vaccines. This is a clear advantage for our universal flu program over conventional influenza vaccines. We are pleased to report our H1N1 preclinical results using pigs, a more natural model for the current influenza pandemic. We look forward to advancing our SynCon universal flu vaccine program toward clinical investigation.”